结肠癌中miR-1231表达变化的临床意义

Clinical significance of changing in miR-1231 expression in colon cancer

目的:观察结肠癌患者组织标本中miR-1231表达的改变,并探讨其相关的临床意义。方法:取鄂东医疗集团黄石市中心医院2016年2月至2017年8月收治的结肠癌患者94例,取癌旁非肿瘤组织作为对照。采用qRT-PCR检测miR-1231的表达。分析miR-1231表达的变化与各临床指标间的相关性。结果:结肠癌组织中miR-1231的2^(-△Ct)值为0.146±0.018,显著低于对照组织的0.282±0.047(P<0.01)。miR-1231的2^(-△Ct)值结肠癌患者的性别、年龄、肿瘤部位、肿瘤大小无相关性(P>0.05)。miR-1231的2^(-△Ct)值在TNM临床III,IV期患者为0.125±0.014,显著低于I,II期患者的0.161±0.028(P<0.05)。miR-1231的2^(-△Ct)值在中、低分化患者为0.131±0.015,显著低于高分化的0.174±0.032(P<0.05)。miR-1231值在淋巴结有转移患者为0.125±0.014,显著低于无转移的0.154±0.020(P<0.05)。Pearson相关分析显示miR-1231表达与患者的临床TNM分析(r=-0.361,P<0.05)、肿瘤分化(r=-0.342,P<0.05)、淋巴结是否转移(r=-0.354,P<0.05)呈负相关。结论:结肠组织中miR-1231低表达,其表达变化可能参与结肠癌的发生、发展、侵袭和转移过程。

Objective： To detect miR-1231 expression in colon cancer and explore its clinical significance. Methods： Ninetyfour patients of colon cancer were enrolled in this study. The non-cancerous tissues beside the tumor were taken as controls. QRT-PCR analysis was used to detect miR-1231 expression. Results： MiR-1231 expression in the colon cancer tissue was 0.146±0.018, which was lower than that of 0.282±0.047 in the control tissue（P〈0.01）. There was no significant correlation of miR-1231 with colon cancer patients’ gender, age, tumor location, and tumor size（P〉0.05）. MiR-1231 expression in III and IV stage group was 0.125±0.014, which was lower than that of 0.161±0.028 in I and II stage group（P〈0.05）. MiR-1231 expression in median and low differentiation group was 0.131±0.015, which was lower than that of 0.174±0.032 in well differentiation group（P〈0.05）. MiR-1231 expression in lymph node metastasis group was 0.125±0.014, which was lower than that of 0.154±0.020 in nonlymph node metastasis group（P〈0.05）. Pearson correlation analysis showed that the expression of miR-1231 was negatively correlated with clinical TNM analysis（r=-0.361, P〈0.05）, tumor differentiation（r=-0.342, P〈0.05）, lymph node metastasis（r=-0.354, P〈0.05）. Conclusion： Low expression of miR-1231 is found in colon cancer, which may be related to clinical stages, lymph node metastasis, and tumor differentiation of bladder cancer.